AUCTORES
Globalize your Research
Research Article | DOI: https://doi.org/10.31579/2692-9759/072
1Endocrinology Division, Department of Medicine, Olive-View-UCLA Medical Center, David-Geffen School of Medicine, CA, USA.
2 Department of Medicine, Olive-View-UCLA Medical Center, David-Geffen School of Medicine, CA, USA.
*Corresponding Author: Nasser Mikhail, Endocrinology Division, Department of Medicine, Olive-View-UCLA Medical Center, David-Geffen School of Medicine, CA, USA.
Citation: N Mikhail, S Wali. (2021) Effects of metformin on clinical outcomes in patients with type 2 diabetes and COVID-19. Journal of Endocrinology and Disorders. 5(3): Doi:10.31579/2640-1045/072
Copyright: © 2021 Nasser Mikhail. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 21 April 2021 | Accepted: 28 April 2021 | Published: 12 May 2021
Keywords: COVID-19; diabetes; metformin; safety; mortality; lactic acidosis
Background: The effects of metformin therapy on the prognosis of patients with coronavirus disease 2019 (COVID-19) are unclear.
Objective: To review effects of metformin on clinical outcomes, particularly mortality, in patients with type 2 diabetes and COVID-19.
Methods: Review of English literature by PUBMED search until April 20, 2021. Search terms included diabetes, COVID-19, metformin, Retrospective studies, meta-analyses, pertinent reviews, and consensus guidelines are reviewed.
Results: All available studies in this area are retrospective. Two population-based studies did not find significant association between metformin use and susceptibility to COVID-19. Most, but not all studies, suggest that metformin use prior to hospital admission might be associated with significant decrease in mortality in patients with type 2 diabetes and COVID-19. Continuing metformin use after hospital admission did not have significant impact on COVID-19 related death but may decrease risk of acute respiratory distress syndrome (ARDS). Meanwhile, in-hospital metformin administration may be associated with approximately 4.6 times increase risk of lactic acidosis in patients with severe symptoms of COVID-19, patients taking ≥2 gm/d of metformin, and patients with estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 kg/m2.
Conclusions: Although most retrospective studies suggest that metformin administration may be associated with decreased risk of COVID-19 mortality, these data should be confirmed by randomized trials. In patients with type 2 diabetes and COVID-19 admitted to the hospital, metformin use should be avoided in presence of severe symptoms of COVID-19, kidney dysfunction (eGFR < 60 ml/min/1.73m2), and in daily doses of ≥ 2 gm due to increased risk of lactic acidosis.
Metformin is the most common anti-diabetic drug worldwide due to its well-established long-term overall high efficacy and safety profile and low cost [1]. The effects of metformin therapy on risk and clinical outcomes in COVID-19 are unclear. The American Diabetes Association (ADA) recommends insulin as the standard therapy for hyperglycemia in hospital [2]. Moreover, the ADA generally recommends stopping all oral anti-diabetic agents in most patients after hospital admission admitted to the hospital due to due to lack of data, presence of adverse effects, and limited efficacy [2]. Meanwhile, metformin might be an exception due to emerging studies showing potential benefits in patients with COVID-19. This review discusses the effects of metformin on susceptibility and prognosis of COVID-19 with special emphasis on its impact on mortality.
Effect of metformin on susceptibility to COVID-19
Two large studies investigated risk of COVID-19 in relation to prior metformin use with different results [3, 4]. In a large population-based study from South Korea, Oh et al [3] performed propensity score matching analysis to compare risk of COVID-19 between patients with type 2 diabetes prescribed metformin (n=5,946) with those not prescribed metformin (5,946). They found that patients prescribed metformin had 30% lower risk of COVID-19 compared with those not prescribed metformin, odds ratio (OR) 0.70 (95% CI 0.61-0.80; P<0.001) [3]. However. in another larger propensity score matching analysis from the UK, Wang et al [4] found no significant difference in incidence of COVID-19 between the group of patients exposed to metformin (n=10,183) and the matched group not exposed to metformin, adjusted hazard ratio (HR) 0.80 (95% CI 0.49-1.30).
Effect of metformin on mortality in patients with COVID-19
Effect of pre-admission use of metformin on mortality
The largest study that examined association of metformin and other glucose-lowering therapies with mortality risk in patients with COVID-19 was conducted by Khunti et al [5] in the UK. This was a nationwide population study including 2,851,465 subjects that represented almost the entire patients with type 2 diabetes in the UK [5]. Overall, COVID-19 related death occurred in 13,479 (0.5%) subjects during the study period from February 16 to August 31st, 2020 [5]. After adjusting for differences in patients’ characteristics, adjusted hazard ratio (HR) for COVID-19 related death was 0.77 (95% CI, 0.73-0.81) for patients prescribed metformin compared with those not prescribed metformin [5]. Corresponding HR for sodium-glucose co-transporter 2 (SGLT2) inhibitors was 0.82 (95% CI, 0.74-0.91) and for sulfonylureas was 0.94 (95% CI 0.89-0.99) [5]. Risk of mortality was not statistically significant with thiazolidinediones HR 0.94 (95% CI 0.82-1.07), and glucagon-like peptide 1 receptor agonists (GLP-1 RA) HR 0.94 (95% CI 83-1.07) [5]. Interestingly, mortality risk was significantly increased with insulin therapy HR 1.43 (95% CI 1.35-1.49) and to a lesser extent with dipeptidyl-peptidase-4 (DPP-4) inhibitors HR 1.07 (95% CI 1.01-1.13) [5]. However, it should be emphasized that these results may be confounded by indication since metformin is usually prescribed in the early course of diabetes as opposed to insulin which is prescribed in more advanced stages of the disease. The CORONADO study is a French nationwide retrospective investigation that included 2,796 patients with type 2 diabetes admitted to the hospital with COVID-19 [6]. After adjusting for multiple variables, the authors found that metformin treatment before admission was significantly associated with lower risk of in-hospital death, OR 0.65 (95% CI 0.45-0.93) and increased hospital discharge within 28 days OR 1.40 (95% CI 1.08-1.81) [6]. In a meta-analysis conducted by Kow and Hasan [7], the authors analyzed data (up to August 8, 2020) of 5 studies including 8,121 patients with diabetes and COVID-19 who were using metformin prior to hospital admission. Their pooled analysis revealed a significantly decreased risk of mortality with the use of metformin prior to admission, pooled OR being 0.62 (95% CI, 0.43-0.89) compared to patients with diabetes who were non-users of metformin [7]. Interestingly, the largest study included in this meta-analysis conducted by Bramante et al [8] showed that pre-admission metformin use was associated with decreased in-hospital mortality in women only, OR 0.78 (95% CI 0.65-0.95), but not in men.
However, not all studies showed mortality reduction in patients with COVID-19 using metformin. In the propensity matched analysis by Wang et al [4] in the UK mentioned earlier, no significant difference in COVID-19-related death was found between metformin users and non-users, adjusted HR 0.87 (95% CI 0.34-2.20). Similarly, in the Korean study by Oh et al [3], metformin use was not associated with in-hospital mortality, adjusted HR 1.26 (95% CI 0.81-1.95).
Taken together, the balance of evidence overall suggests that metformin use might be associated with mortality reduction among patients with type 2 diabetes and COVID-19. However, this conclusion should be considered preliminary due to the following limitations. First, all included studies were retrospective prone for confounding factors. Second, it was not possible to know to what extent patients were adherent to metformin intake prior to hospital admission. Third, it was not clear in any of these studies whether patients continued to take metformin or discontinued it after admission to the hospital.
Effect of in-hospital administration of metformin on mortality
In a relatively large (n=1,213) study from China, Cheng et al [9] have shown that metformin use while in hospital was not associated with 28-day all-cause mortality compared with metformin non-users; adjusted HR 0.87 (95% CI 0.36-2.12; P =0.75). Similarly, in another smaller (n=328) retrospective Chinese study, Jiang et al [10] did not found significant association between metformin use and 30-day mortality. In a third small Chinese studies conducted by Cheng et al [11] including 50 patients with type 2 diabetes admitted for COVID-19, 22 patients continued to take metformin after admission. (median dose 1.0 g/d). Again, the authors found no difference in mortality or fever duration between metformin users and non-users in the hospital [11].
Effects of metformin on other clinical outcomes of COVID-19
Ghany et al [12] conducted a retrospective study including 1,139 COVID-19 positive Medicare elderly patients (mean age 71 years-old) across 8 states in the US. This cohort also included a majority of Black patients (71%) and women (60%) [12]. The authors found that metformin users (n=392) had significantly lower rates of hospitalization compared to metformin non-users; adjusted relative hazard (RH) 0.71 (95% CI 0.52-0.86) [12]. Furthermore, metformin users developed less frequently ARDS compared with non-users, adjusted RH 0.71 (95% CI 0.52-0.86) [12]. In another retrospective study from China, Cheng et al [9] found that metformin in-hospital use was associated with decreased risk of heart failure adjusted HR 0.61 (95% CI 0.43-0.87; P=0.006), and ARDS, adjusted HR 0.66, 95% CI 0.46-0.96; P=0.03). There was no significant effect of metformin on acute kidney injury or disseminated intravascular coagulation [9]. Likewise, Jiang et al [10] found that COVID-19 patients with type 2 diabetes who received metformin during hospitalization had significantly lower risk of ARDS compared with non-metformin users after propensity score matching [adjusted OR 0.16 (95% CI, 0.04-0.72; P= 0.016)].
Dose-dependent effects of metformin in COVID-19
Two retrospective investigations addressed the impact of metformin doses on clinical outcomes in patients with type 2 diabetes COVID-19. In the first study of Medicare patients, Ghany et al [12] reported a dose-effect of metformin in terms of reduced risk of mortality. Thus, patients who were prescribed metformin 500-850 mg/d had HR of mortality of 0.35 (95% CI 0.17-0.71), whereas those patients prescribed metformin at ≥ 1 g/d had HR of mortality of 0.23 (95% CI 0.06-0.78) [12]. Cheng et al [11] noted that the dose of metformin prior to admission showed a negative association with the rate of admission to intensive care unit with borderline statistical significance (OR 0.04, 95% CI 0.00-0.99, P=0.049).
Safety of metformin use during hospitalization of patients with COVID-19
Lactic acidosis is a rare, but potentially lethal adverse effect of metformin [13]. Cheng et al [9] evaluated in-hospital metformin safety in different subgroups of patients admitted with COVID-19 and type 2 diabetes. They found that lactic acidosis was increased among metformin users compared with metformin non-users, adjusted HR 4.66, 95% 1.45-14.99; P=0.01 [9]. Yet, this increased risk of lactic acidosis was limited to the following subgroups of patients: those with severe form of COVID-19, patients using metformin in doses of ≥ 2 g/d, and in presence of kidney dysfunction defined as eGFR <60 ml/min/1.73 kg/m2 [9].
Potential mechanisms underlying metformin clinical benefits
Metformin has been shown to improve the immune response and reduce inflammation [14]. It may also block mTOR pathway which plays a role in the pathogenesis of Middle East respiratory syndrome coronavirus infection [15]. It should be emphasized, however, that metformin should not be used in presence of hypoxia, decreased tissue perfusion, sepsis, acute or chronic kidney disease, and acute heart and liver failure to avoid the risk of lactic acidosis [13].
Preliminary data suggest that metformin use prior to hospitalization of patients with type 2 diabetes and COVID-19 may reduce mortality. Meanwhile, continuing metformin after hospitalization did not affect mortality, but increased risk of lactic acidosis. The risk of lactic acidosis was evident only in patients with severe symptoms of COVID-19, those with kidney dysfunction, and in patients taking ≥2 g of metformin daily. Accordingly, metformin should be discontinued in cases of severe COVID-19 and kidney disease, and its daily doses should not exceed 2 g. On the other hand, metformin in lower doses may be continued in mild cases, and in presence of normal kidney function in view of its possible benefits in reducing risk of ARDS. Unfortunately, all current data related to COVID-19 and metformin are based on retrospective studies prone for multiple bias and confounding factors. Randomized trials are urgently needed to determine safety and efficacy of metformin in hospitalized COVID-19 patients. The COVIDOUT trial (NCT04510194) is a randomized trial that started January 2021 and expected to include 750 participants [16]. The purpose of this study is to see whether metformin treatment in non-hospitalized adults (30-85 years-old) with COVID-19 infection can prevent hypoxia, emergency room utilization, and COVID-19 disease progression [16]. Interestingly, type 2 diabetes is not a requirement to participate in this study. Thus, the results of the COVIDOUT trial should clarify the potential benefits of metformin in patients with COVID-19 irrespective of presence of diabetes [16].
Disclosure
The authors do not have any conflict of interest to disclose.
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
Journal of Clinical Cardiology and Cardiovascular Intervention The submission and review process was adequate. However I think that the publication total value should have been enlightened in early fases. Thank you for all.
Journal of Women Health Care and Issues By the present mail, I want to say thank to you and tour colleagues for facilitating my published article. Specially thank you for the peer review process, support from the editorial office. I appreciate positively the quality of your journal.
Journal of Clinical Research and Reports I would be very delighted to submit my testimonial regarding the reviewer board and the editorial office. The reviewer board were accurate and helpful regarding any modifications for my manuscript. And the editorial office were very helpful and supportive in contacting and monitoring with any update and offering help. It was my pleasure to contribute with your promising Journal and I am looking forward for more collaboration.
We would like to thank the Journal of Thoracic Disease and Cardiothoracic Surgery because of the services they provided us for our articles. The peer-review process was done in a very excellent time manner, and the opinions of the reviewers helped us to improve our manuscript further. The editorial office had an outstanding correspondence with us and guided us in many ways. During a hard time of the pandemic that is affecting every one of us tremendously, the editorial office helped us make everything easier for publishing scientific work. Hope for a more scientific relationship with your Journal.
The peer-review process which consisted high quality queries on the paper. I did answer six reviewers’ questions and comments before the paper was accepted. The support from the editorial office is excellent.
Journal of Neuroscience and Neurological Surgery. I had the experience of publishing a research article recently. The whole process was simple from submission to publication. The reviewers made specific and valuable recommendations and corrections that improved the quality of my publication. I strongly recommend this Journal.
Dr. Katarzyna Byczkowska My testimonial covering: "The peer review process is quick and effective. The support from the editorial office is very professional and friendly. Quality of the Clinical Cardiology and Cardiovascular Interventions is scientific and publishes ground-breaking research on cardiology that is useful for other professionals in the field.
Thank you most sincerely, with regard to the support you have given in relation to the reviewing process and the processing of my article entitled "Large Cell Neuroendocrine Carcinoma of The Prostate Gland: A Review and Update" for publication in your esteemed Journal, Journal of Cancer Research and Cellular Therapeutics". The editorial team has been very supportive.
Testimony of Journal of Clinical Otorhinolaryngology: work with your Reviews has been a educational and constructive experience. The editorial office were very helpful and supportive. It was a pleasure to contribute to your Journal.
Dr. Bernard Terkimbi Utoo, I am happy to publish my scientific work in Journal of Women Health Care and Issues (JWHCI). The manuscript submission was seamless and peer review process was top notch. I was amazed that 4 reviewers worked on the manuscript which made it a highly technical, standard and excellent quality paper. I appreciate the format and consideration for the APC as well as the speed of publication. It is my pleasure to continue with this scientific relationship with the esteem JWHCI.
This is an acknowledgment for peer reviewers, editorial board of Journal of Clinical Research and Reports. They show a lot of consideration for us as publishers for our research article “Evaluation of the different factors associated with side effects of COVID-19 vaccination on medical students, Mutah university, Al-Karak, Jordan”, in a very professional and easy way. This journal is one of outstanding medical journal.
Dear Hao Jiang, to Journal of Nutrition and Food Processing We greatly appreciate the efficient, professional and rapid processing of our paper by your team. If there is anything else we should do, please do not hesitate to let us know. On behalf of my co-authors, we would like to express our great appreciation to editor and reviewers.
As an author who has recently published in the journal "Brain and Neurological Disorders". I am delighted to provide a testimonial on the peer review process, editorial office support, and the overall quality of the journal. The peer review process at Brain and Neurological Disorders is rigorous and meticulous, ensuring that only high-quality, evidence-based research is published. The reviewers are experts in their fields, and their comments and suggestions were constructive and helped improve the quality of my manuscript. The review process was timely and efficient, with clear communication from the editorial office at each stage. The support from the editorial office was exceptional throughout the entire process. The editorial staff was responsive, professional, and always willing to help. They provided valuable guidance on formatting, structure, and ethical considerations, making the submission process seamless. Moreover, they kept me informed about the status of my manuscript and provided timely updates, which made the process less stressful. The journal Brain and Neurological Disorders is of the highest quality, with a strong focus on publishing cutting-edge research in the field of neurology. The articles published in this journal are well-researched, rigorously peer-reviewed, and written by experts in the field. The journal maintains high standards, ensuring that readers are provided with the most up-to-date and reliable information on brain and neurological disorders. In conclusion, I had a wonderful experience publishing in Brain and Neurological Disorders. The peer review process was thorough, the editorial office provided exceptional support, and the journal's quality is second to none. I would highly recommend this journal to any researcher working in the field of neurology and brain disorders.
Dear Agrippa Hilda, Journal of Neuroscience and Neurological Surgery, Editorial Coordinator, I trust this message finds you well. I want to extend my appreciation for considering my article for publication in your esteemed journal. I am pleased to provide a testimonial regarding the peer review process and the support received from your editorial office. The peer review process for my paper was carried out in a highly professional and thorough manner. The feedback and comments provided by the authors were constructive and very useful in improving the quality of the manuscript. This rigorous assessment process undoubtedly contributes to the high standards maintained by your journal.
International Journal of Clinical Case Reports and Reviews. I strongly recommend to consider submitting your work to this high-quality journal. The support and availability of the Editorial staff is outstanding and the review process was both efficient and rigorous.
Thank you very much for publishing my Research Article titled “Comparing Treatment Outcome Of Allergic Rhinitis Patients After Using Fluticasone Nasal Spray And Nasal Douching" in the Journal of Clinical Otorhinolaryngology. As Medical Professionals we are immensely benefited from study of various informative Articles and Papers published in this high quality Journal. I look forward to enriching my knowledge by regular study of the Journal and contribute my future work in the field of ENT through the Journal for use by the medical fraternity. The support from the Editorial office was excellent and very prompt. I also welcome the comments received from the readers of my Research Article.
Dear Erica Kelsey, Editorial Coordinator of Cancer Research and Cellular Therapeutics Our team is very satisfied with the processing of our paper by your journal. That was fast, efficient, rigorous, but without unnecessary complications. We appreciated the very short time between the submission of the paper and its publication on line on your site.
I am very glad to say that the peer review process is very successful and fast and support from the Editorial Office. Therefore, I would like to continue our scientific relationship for a long time. And I especially thank you for your kindly attention towards my article. Have a good day!
"We recently published an article entitled “Influence of beta-Cyclodextrins upon the Degradation of Carbofuran Derivatives under Alkaline Conditions" in the Journal of “Pesticides and Biofertilizers” to show that the cyclodextrins protect the carbamates increasing their half-life time in the presence of basic conditions This will be very helpful to understand carbofuran behaviour in the analytical, agro-environmental and food areas. We greatly appreciated the interaction with the editor and the editorial team; we were particularly well accompanied during the course of the revision process, since all various steps towards publication were short and without delay".
I would like to express my gratitude towards you process of article review and submission. I found this to be very fair and expedient. Your follow up has been excellent. I have many publications in national and international journal and your process has been one of the best so far. Keep up the great work.
We are grateful for this opportunity to provide a glowing recommendation to the Journal of Psychiatry and Psychotherapy. We found that the editorial team were very supportive, helpful, kept us abreast of timelines and over all very professional in nature. The peer review process was rigorous, efficient and constructive that really enhanced our article submission. The experience with this journal remains one of our best ever and we look forward to providing future submissions in the near future.
I am very pleased to serve as EBM of the journal, I hope many years of my experience in stem cells can help the journal from one way or another. As we know, stem cells hold great potential for regenerative medicine, which are mostly used to promote the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives. I think Stem Cell Research and Therapeutics International is a great platform to publish and share the understanding towards the biology and translational or clinical application of stem cells.
I would like to give my testimony in the support I have got by the peer review process and to support the editorial office where they were of asset to support young author like me to be encouraged to publish their work in your respected journal and globalize and share knowledge across the globe. I really give my great gratitude to your journal and the peer review including the editorial office.
I am delighted to publish our manuscript entitled "A Perspective on Cocaine Induced Stroke - Its Mechanisms and Management" in the Journal of Neuroscience and Neurological Surgery. The peer review process, support from the editorial office, and quality of the journal are excellent. The manuscripts published are of high quality and of excellent scientific value. I recommend this journal very much to colleagues.
Dr.Tania Muñoz, My experience as researcher and author of a review article in The Journal Clinical Cardiology and Interventions has been very enriching and stimulating. The editorial team is excellent, performs its work with absolute responsibility and delivery. They are proactive, dynamic and receptive to all proposals. Supporting at all times the vast universe of authors who choose them as an option for publication. The team of review specialists, members of the editorial board, are brilliant professionals, with remarkable performance in medical research and scientific methodology. Together they form a frontline team that consolidates the JCCI as a magnificent option for the publication and review of high-level medical articles and broad collective interest. I am honored to be able to share my review article and open to receive all your comments.
“The peer review process of JPMHC is quick and effective. Authors are benefited by good and professional reviewers with huge experience in the field of psychology and mental health. The support from the editorial office is very professional. People to contact to are friendly and happy to help and assist any query authors might have. Quality of the Journal is scientific and publishes ground-breaking research on mental health that is useful for other professionals in the field”.
Dear editorial department: On behalf of our team, I hereby certify the reliability and superiority of the International Journal of Clinical Case Reports and Reviews in the peer review process, editorial support, and journal quality. Firstly, the peer review process of the International Journal of Clinical Case Reports and Reviews is rigorous, fair, transparent, fast, and of high quality. The editorial department invites experts from relevant fields as anonymous reviewers to review all submitted manuscripts. These experts have rich academic backgrounds and experience, and can accurately evaluate the academic quality, originality, and suitability of manuscripts. The editorial department is committed to ensuring the rigor of the peer review process, while also making every effort to ensure a fast review cycle to meet the needs of authors and the academic community. Secondly, the editorial team of the International Journal of Clinical Case Reports and Reviews is composed of a group of senior scholars and professionals with rich experience and professional knowledge in related fields. The editorial department is committed to assisting authors in improving their manuscripts, ensuring their academic accuracy, clarity, and completeness. Editors actively collaborate with authors, providing useful suggestions and feedback to promote the improvement and development of the manuscript. We believe that the support of the editorial department is one of the key factors in ensuring the quality of the journal. Finally, the International Journal of Clinical Case Reports and Reviews is renowned for its high- quality articles and strict academic standards. The editorial department is committed to publishing innovative and academically valuable research results to promote the development and progress of related fields. The International Journal of Clinical Case Reports and Reviews is reasonably priced and ensures excellent service and quality ratio, allowing authors to obtain high-level academic publishing opportunities in an affordable manner. I hereby solemnly declare that the International Journal of Clinical Case Reports and Reviews has a high level of credibility and superiority in terms of peer review process, editorial support, reasonable fees, and journal quality. Sincerely, Rui Tao.
Clinical Cardiology and Cardiovascular Interventions I testity the covering of the peer review process, support from the editorial office, and quality of the journal.
